Literature DB >> 8114074

Gentamicin resistance in clinical isolates of Escherichia coli encoded by genes of veterinary origin.

A P Johnson1, L Burns, N Woodford, E J Threlfall, J Naidoo, E M Cooke, R C George.   

Abstract

Seven (27%) of 26 gentamicin-resistant human clinical isolates of Escherichia coli were resistant to the veterinary aminoglycoside antibiotic apramycin. A gentamicin-resistant Klebsiella pneumoniae isolate from a patient infected with gentamicin/apramycin-resistant E. coli was also resistant to apramycin. DNA hybridisation studies showed that all gentamicin/apramycin-resistant isolates contained a gene encoding the enzyme 3-N-aminoglycoside acetyltransferase type IV (AAC[3]IV) that mediates resistance to gentamicin and apramycin in bacteria isolated from animals. Seven of the eight gentamicin/apramycin-resistant isolates were also resistant to the veterinary antihelminthic agent hygromycin B, a phenomenon observed previously in gentamicin/apramycin-resistant Enterobacteriaceae isolated from animals. Resistance to gentamicin/apramycin and hygromycin B was co-transferable in six of the isolates. Restriction enzyme analysis of plasmids in apramycin-resistant transconjugants derived from E. coli and K. pneumoniae isolates from the same patient were virtually identical, suggesting that inter-generic transfer of plasmids encoding apramycin resistance had occurred in vivo. These findings support the view that resistance to gentamicin and apramycin in clinical isolates of E. coli results from the spread of resistant organisms from animals to man, with subsequent inter-strain or inter-species spread, or both, of resistance genes on transferable plasmids.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8114074     DOI: 10.1099/00222615-40-3-221

Source DB:  PubMed          Journal:  J Med Microbiol        ISSN: 0022-2615            Impact factor:   2.472


  7 in total

1.  Biogenic Synthesis of ZnO Nanoparticles and Its Potential Use as Antimicrobial Agent Against Multidrug-Resistant Pathogens.

Authors:  Sanaa M F Gad El-Rab; Aly E Abo-Amer; Ahlam M Asiri
Journal:  Curr Microbiol       Date:  2020-04-23       Impact factor: 2.188

2.  Heterogeneity among virulence and antimicrobial resistance gene profiles of extraintestinal Escherichia coli isolates of animal and human origin.

Authors:  Christine Maynard; Sadjia Bekal; François Sanschagrin; Roger C Levesque; Roland Brousseau; Luke Masson; Serge Larivière; Josée Harel
Journal:  J Clin Microbiol       Date:  2004-12       Impact factor: 5.948

3.  Antimicrobial resistance and virulence genes of Escherichia coli isolates from swine in Ontario.

Authors:  Patrick Boerlin; Rebeccah Travis; Carlton L Gyles; Richard Reid-Smith; Nicol Janecko; Heather Lim; Vivian Nicholson; Scott A McEwen; Robert Friendship; Marie Archambault
Journal:  Appl Environ Microbiol       Date:  2005-11       Impact factor: 4.792

4.  Recovery of cephalosporin-resistant Escherichia coli and Salmonella from pork, beef and chicken marketed in Nova Scotia.

Authors:  Kevin R Forward; Katherine M Matheson; Margot Hiltz; Heather Musgrave; Cornelius Poppe
Journal:  Can J Infect Dis Med Microbiol       Date:  2004-07       Impact factor: 2.471

5.  Urinary isolates of apramycin-resistant Escherichia coli and Klebsiella pneumoniae from Dublin.

Authors:  A P Johnson; M Malde; N Woodford; R J Cunney; E G Smyth
Journal:  Epidemiol Infect       Date:  1995-02       Impact factor: 2.451

6.  Apramycin treatment affects selection and spread of a multidrug-resistant Escherichia coli strain able to colonize the human gut in the intestinal microbiota of pigs.

Authors:  Ana Herrero-Fresno; Camilla Zachariasen; Monica Hegstad Hansen; Alexander Nielsen; Rene S Hendriksen; Søren Saxmose Nielsen; John Elmerdahl Olsen
Journal:  Vet Res       Date:  2016-01-07       Impact factor: 3.683

7.  Wild-type cutoff for Apramycin against Escherichia coli.

Authors:  Yuqi Yang; Tianshi Xiao; Jiarui Li; Ping Cheng; Fulei Li; Hongxiao Yu; Ruimeng Liu; Ishfaq Muhammad; Xiuying Zhang
Journal:  BMC Vet Res       Date:  2020-08-26       Impact factor: 2.741

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.